Patient and disease characteristics tested for association with achievement of inactive disease state.
| Characteristic | Patients with Inactive Disease, n/total | Person-yrs | Incidence Rate of Inactive Disease, × 100 person-yrs (95% CI) | p* |
|---|---|---|---|---|
| Sex | ||||
| Female | 61/123 | 201.7 | 30.2 (23.5–38.9) | 0.94 |
| Male | 23/50 | 83.7 | 27.5 (18.3–41.4) | |
| Age at disease onset, yrs | ||||
| < 3.6 | 49/83 | 130.9 | 37.4 (28.3–49.5) | 0.006 |
| ≥ 3.6 | 35/85 | 154.5 | 22.7 (16.3–31.6) | |
| Disease duration at start of etanercept, yrs | ||||
| < 2 | 20/43 | 57 | 35.1 (22.6–54.4) | 0.77 |
| ≥ 2 | 64/125 | 228.4 | 28.0 (21.9–35.8) | |
| Interval between first observation and start of etanercept, yr | ||||
| < 1 | 22/45 | 71.5 | 30.8 (20.3–46.7) | 0.89 |
| ≥ 1 | 60/118 | 198.8 | 30.2 (23.4–38.9) | |
| Age at start of etanercept, yrs | ||||
| < 10 | 42/84 | 150.3 | 27.9 (20.7–37.8) | 0.66 |
| ≥ 10 | 42/84 | 135.1 | 31.1 (23.0–42.1) | |
| ILAR category | ||||
| Systemic arthritis | 7/24 | 52.5 | 13.3 (6.4–28.0) | 0.07 |
| Nonsystemic categories | 77/144 | 232.9 | 33.1 (26.4–41.3) | |
| Antinuclear antibody status | ||||
| Positive | 55/102 | 164.2 | 33.5 (25.7–43.6) | 0.23 |
| Negative | 27/63 | 119.1 | 22.7 (15.5–33.1) | |
| JIA outcome measures at start of etanercept | ||||
| Physician global assessment VAS score, cm | ||||
| ≥ 6 | 34/75 | 140.5 | 24.2 (17.3–33.9) | 0.06 |
| < 6 | 43/75 | 98.0 | 43.9 (32.6–59.2) | |
| No. active joints | ||||
| ≥ 5 | 37/80 | 146.7 | 25.2 (18.3–34.8) | 0.10 |
| < 5 | 40/70 | 92.1 | 43.4 (31.9–59.2) | |
| Erythrocyte sedimentation rate, mm/h | ||||
| ≥ 40 | 37/74 | 117.3 | 31.5 (22.9–43.5) | 0.98 |
| < 40 | 39/75 | 107.4 | 36.3 (26.5–49.7) | |
| C-reactive protein, mg/dl | ||||
| ≥ 1.5 | 31/70 | 125.1 | 24.8 (17.4–35.2) | 0.11 |
| < 1.5 | 44/76 | 90 | 48.9 (36.4–65.7) | |
| Joints affected before start of etanercept | ||||
| Cervical spine | ||||
| Yes | 10/27 | 41.4 | 24.2 (13.0–44.9) | 0.39 |
| No | 74/141 | 244.0 | 30.3 (24.1–38.1) | |
| Wrist | ||||
| Yes | 28/77 | 173.2 | 16.2 (11.2–23.4) | 0.0001 |
| No | 56/91 | 112.2 | 49.9 (38.4–64.9) | |
| Hand joints | ||||
| Yes | 42/93 | 178.7 | 23.5 (17.4–31.8) | 0.06 |
| No | 42/75 | 106.7 | 39.4 (29.1–53.3) | |
| Hip | ||||
| Yes | 18/40 | 91.6 | 19.7 (12.4–31.2) | 0.31 |
| No | 66/128 | 193.8 | 34.1 (26.8–43.3) | |
| Knee | ||||
| Yes | 62/132 | 237 | 26.2 (20.4–33.6) | 0.15 |
| No | 22/36 | 48.4 | 45.5 (29.9–69.0) | |
| Ankle | ||||
| Yes | 66/126 | 207.2 | 31.9 (25.0–40.5) | 0.24 |
| No | 18/42 | 78.2 | 23.0 (14.5–36.5) | |
| Use of medications before start of etanercept | ||||
| Systemic corticosteroids | ||||
| Yes | 26/66 | 126.9 | 20.5 (13.9–30.1) | 0.04 |
| No | 58/102 | 158.5 | 36.6 (28.3–47.3) | |
| Methotrexate | ||||
| Yes | 79/160 | 276.3 | 28.6 (22.9–35.6) | 0.73 |
| No | 5/8 | 9.1 | 54.9 (22.9–132.0) | |
| Intraarticular corticosteroids | ||||
| Yes | 59/122 | 185.0 | 31.9 (24.7–41.2) | 0.99 |
| No | 25/46 | 100.4 | 24.9 (16.8–36.9) | |
| Concomitant medications during etanercept administration | ||||
| Systemic corticosteroids | ||||
| Yes | 7/21 | 42.5 | 16.5 (7.8–34.5) | 0.14 |
| No | 77/147 | 242.0 | 31.8 (25.4–39.8) | |
| Methotrexate | ||||
| Yes | 50/111 | 204.5 | 24.4 (18.5–32.3) | 0.07 |
| No | 34/57 | 80.0 | 42.5 (30.4–59.5) | |
| Intraarticular corticosteroids | ||||
| Yes | 10/37 | 120.3 | 8.3 (4.5–15.4) | 0.0003 |
| No | 74/131 | 164.3 | 45.0 (35.9–56.6) |
↵* Log-rank test. ILAR: International League of Associations for Rheumatology; JIA: juvenile idiopathic arthritis.